MARKET

ITCI

ITCI

Intra Cellular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.88
+0.15
+0.26%
Closed 18:25 05/20 EDT
OPEN
58.50
PREV CLOSE
57.73
HIGH
59.85
LOW
55.55
VOLUME
873.85K
TURNOVER
--
52 WEEK HIGH
66.00
52 WEEK LOW
28.40
MARKET CAP
5.46B
P/E (TTM)
-15.9770
1D
5D
1M
3M
1Y
5Y
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Investor's Business Daily · 05/11 19:55
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
Benzinga · 05/10 18:49
Intra-Cellular rises 18% as robust demand for bipolar depression drug drives Q1 beat
Intra-Cellular Therapies (NASDAQ:ITCI +18.1%) is trading higher after the company posted better-than-expected Q1 revenue, helped by robust demand for its bipolar depression drug, Caplyta. Net product revenues of Caplyta rose 123%
Seekingalpha · 05/10 17:12
Sector Update: Health Care Stocks Carried Higher by Surging Biotechs
MT Newswires · 05/10 16:02
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 12:45
Update: Intra-Cellular Therapies Q1 Loss Expands; Revenue Rises; Shares Rise Tuesday Afternoon
MT Newswires · 05/10 12:27
More
No Data
Learn about the latest financial forecast of ITCI. Analyze the recent business situations of Intra Cellular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

41.67%Strong Buy
50.00%Buy
8.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ITCI stock price target is 71.80 with a high estimate of 90.00 and a low estimate of 57.00.
High90.00
Average71.80
Low57.00
Current 57.88
EPS
Actual
Estimate
-0.84-0.63-0.42-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 300
Institutional Holdings: 85.50M
% Owned: 90.65%
Shares Outstanding: 94.32M
TypeInstitutionsShares
Increased
87
7.46M
New
64
9.23M
Decreased
59
3.58M
Sold Out
31
1.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/President/Chief Executive Officer/Director
Sharon Mates
Chief Financial Officer/Senior Vice President - Finance/Treasurer/Assistant Secretary
Lawrence Hineline
Executive Vice President/General Counsel/Secretary
Michael Halstead
Executive Vice President
Suresh Durgam
Executive Vice President
Mark Neumann
Lead Director/Independent Director
Robert Van Nostrand
Independent Director
Joel Marcus
Independent Director
Michael Rawlins
Independent Director
Rory Riggs
Independent Director
E. Rene Salas
No Data
No Data
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.